Computational Modeling of Network Topology and Molecular Dynamics for the Assessment of Therapeutic Potential of the Astragalus Membranaceus-Salvia Miltiorrhiza Drug Pair in the Treatment of Chronic Kidney and Heart Failure
DOI:
https://doi.org/10.61882/ijkd.19.2.69Keywords:
Astragalus membranaceus-Salvia miltiorrhiza, Chronic kidney disease, Chronic heart failure, Network pharmacology, Molecular dynamics simulationAbstract
Introduction. The bioactive components of Astragalus membranaceus and Salvia miltiorrhiza improved cardiac and renal function in chronic heart failure (CHF) and chronic kidney disease (CKD), respectively. However, the common regulating molecular mechanisms remain unclear. The aim of this study was to investigate these mechanisms using bioinformatics, network topology, and molecular dynamics simulation techniques.
Methods. The active components and target sites of A. membranaceus and S. miltiorrhiza were obtained from the Traditional Chinese Medicine Systems Pharmacology database. The targets of CKD and CHF were obtained from various databases for a protein-protein interaction analysis. The Gene Ontology (GO) function and Kyotoencyclopedia of genes and genomes (KEGG) pathway enrichment of intersection targets were analyzed by using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database. Molecular docking and dynamic simulations were conducted on the core ingredients and targets. The diagnostic efficiency of the key targets was evaluated by using receiver-operating characteristic (ROC) curves.
Results. A total of 70 active ingredients and 158 common targets were found. The top five core targets were AKT1, STAT3, TP53, MAPK1, and RELA. The GO enrichment analysis included apoptosis and oxidative stress. The KEGG pathway enrichment results indicated that the drug pair regulated the AGE-receptor for AGE signaling pathway, fluid shear stress and atherosclerosis, and the IL-17 signaling pathway. Molecular docking and dynamic simulations confirmed that the core ingredients had good affinity and stability with the key targets. The ROC curves confirmed the accuracy of every key target for identifying CKD and CHF and demonstrated that combining them improves diagnosis.
Conclusion. The combination of A. membranaceus and S. miltiorrhiza proved effective for the treatment of CKD and CHF through various components, targets, and mechanisms. Moreover, it may predict the diagnostic value of key targets, providing a reference for clinical diagnostic applications.
Downloads
References
1. Wang R, Hu B, Ye C, Zhang Z, Yin M, Cao Q, et al. Stewed rhubarb decoction ameliorates adenine-induced chronic renal failure in mice by regulating gut microbiota dysbiosis. Frontiers in Pharmacology. 2022;13:842720.
2. Zhang R, Saredy J, Shao Y, Yao T, Liu L, Saaoud F, et al. End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs-A novel multiple-hit model for disease progression. Redox biology. 2020;34:101460.
3. van den Brand JA, Mutsaers HA, van Zuilen AD, Blankestijn PJ, van den Broek PH, Russel FG, et al. Uremic solutes in chronic kidney disease and their role in progression. PLoS One. 2016;11(12):e0168117.
4. Tuttle KR, Brosius Iii FC, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Diabetes. 2021;70(1):1–16.
5. Wang X, Li C, Gong H. Morphological and functional changes in bone marrow mesenchymal stem cells in rats with heart failure. Experimental and therapeutic medicine. 2017;13(6):2888-92.
6. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004-9.
7. Curaj A, Vanholder R, Loscalzo J, et al. Cardiovascular consequences of uremic metabolites: an overview of the involved signaling pathways. Circ Res. 2024;134(5):592–613.
8. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840-e78.
9. He X, Li G, Chen Y, Xiao Q, Yu X, Yu X, et al. Pharmacokinetics and pharmacodynamics of the combination of rhein and curcumin in the treatment of chronic kidney disease in rats. Frontiers in Pharmacology. 2020;11:573118.
10. Fan C, Tang X, Ye M, Zhu G, Dai Y, Yao Z, et al. Qi-Li-Qiang-Xin alleviates isoproterenol-induced myocardial injury by inhibiting excessive autophagy via activating AKT/mTOR pathway. Frontiers in Pharmacology. 2019;10:1329.
11. Ren C, Zhao X, Liu K, Wang L, Chen Q, Jiang H, et al. Research progress of natural medicine Astragalus mongholicus Bunge in treatment of myocardial fibrosis. Journal of Ethnopharmacology. 2023:116128.
12. Li W, Jiang Y-h, Wang Y, Zhao M, Hou G-j, Hu H-z, et al. Protective effects of combination of radix astragali and radix salviae miltiorrhizae on kidney of spontaneously hypertensive rats and renal intrinsic cells. Chinese Journal of Integrative Medicine. 2020;26:46-53.
13. Huang K-C, Su Y-C, Sun M-F, Huang S-T. Chinese herbal medicine improves the long-term survival rate of patients with chronic kidney disease in Taiwan: a nationwide retrospective population-based cohort study. Frontiers in Pharmacology. 2018;9:1117.
14. Chen Y-C, Chen H-T, Yeh C-C, Hung S-K, Yu B-H. Four prescribed Chinese herbal medicines provide renoprotection and survival benefit without hyperkalemia risk in patients with advanced chronic kidney disease: A nationwide cohort study. Phytomedicine. 2022;95:153873.
15. Li M, Han B, Zhao H, Xu C, Xu D, Sieniawska E, et al. Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases. Phytomedicine. 2022;98:153918.
16. Yuan T, Chen Y, Zhou X, Lin X, Zhang Q. Effectiveness and safety of Danshen injection on heart failure: protocol for a systematic review and meta-analysis. Medicine. 2019;98(22).
17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews. 2012;64:4-17.
18. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:1–6.
19. Xu X, Zhang W, Huang C, Li Y, Yu H, Wang Y, et al. A novel chemometric method for the prediction of human oral bioavailability. International journal of molecular sciences. 2012;13(6):6964-82.
20. Uniprot Consortium. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res.2025;53(D1):D609–17.
21. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2012;41(D1):D991–5.
22. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54(1):1–30.
23. Lee-Barber J, Kulo V, Lehmann H, Hamosh A, Bodurtha J. Bioinformatics for medical students: a 5-year experience using OMIM® in medical student educationGenet Med. 2019;21(2):493–7.
24. Zhou Y, Zhang Y, Zhao D, et al. TTD: therapeutic target database describing target druggability information. Nucleic Acids Res. 2024;52(D1):D1465–77.
25. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.
26. Knox C, Wilson M, Klinger CM, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):D1265–75.
27. Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15:1–7.
28. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
29. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein--protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–46.
30. Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–21.
31. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–42.
32. Hsin K-Y, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PloS one. 2013;8(12):e83922.
33. Ould Setti M, Voutilainen A, Tuomainen TP. Renal hyperfiltration, fatty liver index, and the hazards of all-cause and cardiovascular mortality in Finnish men. Epidemiol Health. 2021;43:e2021001.
34. Hughes RL, Alvarado DA, Swanson KS, Holscher HD. The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review. Adv Nutr. 2022;13(2):492–529.
35. Lai Y, Zhu Y, Zhang X, et al. Gut microbiota-derived metabolites: Potential targets for cardiorenal syndrome. Pharmacol Res. 2025;214:107672.
36. Chen Y-Q, Chen H-Y, Tang Q-Q, Li Y-F, Liu X-S, Lu F-H, et al. Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines. Frontiers in Pharmacology. 2022;13:968226.
37. Dong Y, Lei J, Zhang B. Effects of dietary quercetinon the antioxidative status and cecal microbiota in broiler chickens fed with oxidized oil. Poultry science. 2020;99(10):4892-903.
38. Wang L, Tan A, An X, Xia Y, Xie Y. Quercetin dihydrate inhibition of cardiac fibrosis induced by angiotensin II in vivo and in vitro. Biomedicine & Pharmacotherapy. 2020;127:110205.
39. Sharma D, Gondaliya P, Tiwari V, Kalia K. Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. Biomedicine & Pharmacotherapy. 2019;109:1610-9.
40. Suchal K, Malik S, Khan SI, Malhotra RK, Goyal SN, Bhatia J, et al. Molecular pathways involved in the amelioration of myocardial injury in diabetic rats by kaempferol. International Journal of Molecular Sciences. 2017;18(5):1001.
41. Yong C, Zhang Z, Huang G, Yang Y, Zhu Y, Qian L, et al. Exploring the critical components and therapeutic mechanisms of Perilla frutescens L. in the treatment of chronic kidney disease via network pharmacology. Frontiers in pharmacology. 2021;12:717744.
42. Yan Q, Li Y, Yan J, Zhao Y, Liu Y, Liu S. Effects of luteolin on regulatory proteins and enzymes for myocyte calcium circulation in hypothermic preserved rat heart. Exp Ther Med. 2018;15(2):1433–41.
43. Wang X, Li C, Wang Q, Li W, Guo D, Zhang X, et al. Tanshinone IIA restores dynamic balance of autophagosome/autolysosome in doxorubicin-induced cardiotoxicity via targeting beclin1/LAMP1. Cancers. 2019;11(7):910.
44. Wang D-T, Huang R-H, Cheng X, Zhang Z-H, Yang Y- J, Lin X. Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats. International immunopharmacology. 2015;26(1):4-12.
45. Taguchi K, Elias BC, Brooks CR, Ueda S, Fukami K. Uremic toxin–targeting as a therapeutic strategy for preventing cardiorenal syndrome. Circulation Journal. 2019;84(1):2-8.
46. Wang C-C, Lee A-S, Liu S-H, Chang K-C, Shen M-Y, Chang C-T. Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model. BMC nephrology. 2019;20(1):1-13.
47. Paradela-Dobarro B, Agra RM, Álvarez L, Varela-Román A, García-Acuña JM, González-Juanatey JR, et al. The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings. Nutrition, Metabolism and Cardiovascular Diseases. 2019;29(10):1050-60.
48. Neviere R, Yu Y, Wang L, Tessier F, Boulanger E. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions. Glycoconjugate journal. 2016;33:607-17.
49. Gao W, Zhou Z, Liang B, Huang Y, Yang Z, Chen Y, et al. Inhibiting receptor of advanced glycation end products attenuates pressure overload-induced cardiac dysfunction by preventing excessive autophagy. Frontiers in Physiology. 2018;9:1333.
50. Baeyens N, Bandyopadhyay C, Coon BG, Yun S, Schwartz MA. Endothelial fluid shear stress sensing in vascular health and disease. The Journal of clinical investigation. 2016;126(3):821-8.
51. Zhang J, Patel MB, Griffiths R, Mao A, Song Y-s, Karlovich NS, et al. Tumor necrosis factor-α produced in the kidney contributes to angiotensin II–dependent hypertension. Hypertension. 2014;64(6):1275-81.
52. Wen Y, Lu X, Ren J, Privratsky JR, Yang B, Rudemiller NP, et al. KLF4 in macrophages attenuates TNFα-mediated kidney injury and fibrosis. Journal of the American Society of Nephrology: JASN. 2019;30(10):1925.
53. Sun B, Wang H, Zhang L, Yang X, Zhang M, Zhu X, et al. Role of interleukin 17 in TGF-β signaling-mediated renal interstitial fibrosis. Cytokine. 2018;106:80-8.
54. Xue G-l, Li D-s, Wang Z-y, Liu Y, Yang J-m, Li C-z, et al. Interleukin-17 upregulation participates in the pathogenesis of heart failure in mice via NF-κB-dependent suppression of SERCA2a and Cav1. 2 expression. Acta Pharmacologica Sinica. 2021;42(11):1780-9.
55. Kim IY, Lee MY, Park MW, Seong EY, Lee DW, Lee SB, et al. Deletion of Akt1 promotes kidney fibrosis in a murine model of unilateral ureteral obstruction. BioMed Research International. 2020;2020.
56. Kapustian L, Kroupskaya I, Rozhko O, Bobyk V, Ryabenko D, Sidorik L. Akt1 expression and activity at different stages in experimental heart failure. Pathophysiology. 2014;21(2):147-51.
57. Eid RA, Alkhateeb MA, Eleawa S, Al-Hashem FH,Al-Shraim M, El-Kott AF, et al. Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling. Basic research in cardiology. 2018;113:1-16.
58. Nural-Guvener H, Zakharova L, Feehery L, Sljukic S, Gaballa M. Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. International journal of molecular ciences. 2015;16(5):11482-99.
59. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney international. 2010;78(3):257-68.
60. Hoshino A, Mita Y, Okawa Y, Ariyoshi M, Iwai-Kanai E, Ueyama T, et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nature communications. 2013;4(1):2308.
61. Wang J, Pan J, Li H, Long J, Fang F, Chen J, et al. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy. Molecular Therapy-Nucleic Acids. 2018;12:741-50.
62. Li Z, Xu K, Zhang N, Amador G, Wang Y, Zhao S, et al. Overexpressed SIRT6 attenuates cisplatin-induced acute kidney injury by inhibiting ERK1/2 signaling. Kidney international. 2018;93(4):881-92.
63. Ulm S, Liu W, Zi M, Tsui H, Chowdhury SK, Endo S, et al. Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction. Journal of Molecular and Cellular Cardiology. 2014;72:104-16.
64. Danilewicz M, Wągrowska-Danilewicz M. The immunoexpression of glomerular NF-κB in proteinuric patients with proliferative and non-proliferative glomerulopathies. Polish Journal of Pathology. 2013;64(2):78-83.
65. Katare PB, Bagul PK, Dinda AK, Banerjee SK. Toll-like receptor 4 inhibition improves oxidative stress and mitochondrial health in isoproterenol-induced cardiac ypertrophy in rats. Frontiers in immunology. 2017;8:719.
66. Ren Q, Guo F, Tao S, Huang R, Ma L, Fu P. Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice. Biomedicine & Pharmacotherapy. 2020;122:109772.
67. Sun H-J, Xiong S-P, Cao X, Cao L, Zhu M-Y, Wu Z-Y, et al. Polysulfide-mediated sulfhydration of SIRT1 prevents diabetic nephropathy by suppressing phosphorylation and acetylation of p65 NF-κB and STAT3. Redox biology. 2021;38:101813.
